Hepatitis B triple positive, high bilirubin and normal aminotransferases need to be combined with hepatitis B DNA to determine whether to treat, if hepatitis B DNA is positive, antiviral treatment is needed, if hepatitis B DNA is negative, antiviral treatment is not needed, regular review and follow-up can be. If further examination of hepatitis B DNA is positive, it means that the virus is replicating in the body and is highly contagious, even if the indicators of liver function transaminase and bilirubin are normal, antiviral treatment is needed, and the commonly used antiviral drugs include entecavir and tenofovir disoproxil fumarate, and so on. Domestic and international guidelines point out that the presence of immune activation, i.e., abnormal liver function, or cirrhosis or hepatocellular carcinoma has already occurred, or there is a family history of cirrhosis or hepatocellular carcinoma, etc., is an indication for antiviral treatment. Women with HBV-DNA greater than 4 times 10 before pregnancy (multiple retrospective studies suggest a higher probability of mother-to-child transmission in this group). Patients with hepatitis B teratitis B do not require treatment if they have a normal hepatitis B DNA test, normal liver function, no manifestations of acute hepatitis, and no cirrhosis. Regular rechecking of hepatitis B two-to-half, hepatitis B DNA, liver function and other indicators is sufficient. Hepatitis B triple Yang patients should go to the Department of Infectious Diseases or liver disease specialists, and follow the doctor’s instructions for treatment and follow-up.